MaxCyte (NASDAQ:MXCT) has signed a strategic platform license agreement with Adicet Bio for the use of MaxCyte's Flow Electroporation® technology and ExPERT™ platform. The non-exclusive license grants Adicet Bio research, clinical, and commercial rights to support their gamma delta T cell therapy gene edited programs.
Under the agreement, MaxCyte will receive platform licensing fees and program-related revenue. Adicet Bio will utilize MaxCyte's technology to enhance their proprietary manufacturing process for allogeneic gamma delta T cell therapies, aimed at treating cancer and autoimmune diseases.
The collaboration leverages MaxCyte's ExPERT™ platform, which provides high transfection efficiency, cell viability, and seamless scalability for complex cell engineering applications.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.